Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin

International Journal of Molecular Sciences(2023)10.3390/ijms242216109Source: DataRank Database

Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin is a research paper published in International Journal of Molecular Sciences (2023). On theSindex it has a DataRank of 0.470. It has been cited 22 times.

N/A

0.470DataRank · unranked

Scored on demand from live citation data

Open Access22 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (15 grants)OA: goldTopics (26)IDs (PubMed, PMC)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.470

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (7)

Caroline A. Nebhan ORCID,Sally J. York ORCID,Nancy B. Davis ORCID,Paula J. Hurley ORCID,Jennifer Gordetsky ORCID

Live enrichment

PubMed:38003302 PMC:PMC10671469

National Cancer Institute

Grant: F32CA254070

National Cancer Institute

Grant: T32CA217834

National Cancer Institute

Grant: K12CA090625

National Cancer Institute

Grant: P30CA068485

National Cancer Institute

Grant: S10 OD023475-01A1

National Cancer Institute

Grant: S10 OD016355

NIH HHS

Grant: S10 OD023475

BLRD VA

Grant: IS1 BX003154

National Institutes of Health

Grant: 1IS1BX003154-01

Arcturus XT-TI Laser Capture Microdissection Instrument

National Institutes of Health

Grant: 5T32CA217834-04

VIMORTP (Vanderbilt Integrated Molecular Oncology Research Training Program)

National Institutes of Health

Grant: 2K12CA090625-06

Vanderbilt Clinical Oncology Research Career Development Program

National Institutes of Health

Grant: 1S10OD016355-01A1

Pannoramic 250 BF Flash Tissue Microarray system

National Institutes of Health

Grant: 5F32CA254070-02

Investigating concurrent Ras-pathway inhibition to optimize response to anti-PD-1 therapy in NRAS-mutant melanoma

National Institutes of Health

Grant: 1S10OD023475-01A1

Leica Bond RX

National Institutes of Health

Grant: 3P30CA068485-23S2

Cancer Center Support Grant

goldLicense: cc-by

publisherhttps://www.mdpi.com/1422-0067/24/22/16109/pdf?version=1699511651

publisherhttps://www.mdpi.com/1422-0067/24/22/16109/pdf

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10671469/pdf/ijms-24-16109.pdf

Europe_PMChttps://europepmc.org/articles/PMC10671469

Europe_PMChttps://europepmc.org/articles/PMC10671469?pdf=render

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

PenisHumansCarcinoma, Squamous CellPenile NeoplasmsAntibodies, MonoclonalImmunoconjugatesMaleUrinary Bladder NeoplasmsNectins

Keywords

Targeted TherapyAntibody-drug ConjugateNectin-4Penile Squamous Cell CarcinomaMetastatic Penile CancerMaleImmunoconjugatesUrinary Bladder NeoplasmsNectinsCarcinoma, Squamous CellHumansAntibodies, MonoclonalCase ReportPenile NeoplasmsPenis

Sustainable Development Goals

SDG 3: 3. Good health